WO2001074847A2 - Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer - Google Patents

Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer Download PDF

Info

Publication number
WO2001074847A2
WO2001074847A2 PCT/US2001/010312 US0110312W WO0174847A2 WO 2001074847 A2 WO2001074847 A2 WO 2001074847A2 US 0110312 W US0110312 W US 0110312W WO 0174847 A2 WO0174847 A2 WO 0174847A2
Authority
WO
WIPO (PCT)
Prior art keywords
vector
cancer
mammal
polypeptide
immune response
Prior art date
Application number
PCT/US2001/010312
Other languages
English (en)
Other versions
WO2001074847A3 (fr
Inventor
Monica Panelli
Maria Bettinotti
Francesco Marincola
Original Assignee
The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services filed Critical The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services
Priority to AU2001253029A priority Critical patent/AU2001253029A1/en
Publication of WO2001074847A2 publication Critical patent/WO2001074847A2/fr
Publication of WO2001074847A3 publication Critical patent/WO2001074847A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • the present invention relates to an isolated and purified polypeptide consisting essentially of the amino acid sequence VRIGHLYIL and related nucleic acids, vectors and cells as well as compositions comprising the same and methods of using the same to induce an immune response to cancer. .
  • the MAGE family of genes encodes human tumor rejection antigen precursors.
  • Various genes of the MAGE family are expressed in tumor cells.
  • Studies of the MAGE family of genes have revealed that a particular nonapeptide of MAGE- 1 is presented on the surface of some tumor cells by the cell-surface MHC-class I molecule HLA-A1.
  • HLA-A1 complexes with the tumor rejection antigen of MAGE-1
  • the antigen is presented to a cytolytic T cell, which lyses the presenting cell.
  • Comparisons of various MAGE genes to the region of the MAGE-1 gene coding for the nonapeptide indicated that there are homologous sequences in other MAGE genes (U.S. Patent No. 5,851,523).
  • a family of MAGE-derived nonapeptides having the same N- and C-terminal amino acids has been identified.
  • Nonapeptides are of sufficient size to constitute an antigenic epitope. Antibodies generated to such nonapeptides can identify the nonapeptide alone or as part of a larger polypeptide. Like MAGE- 1 , MAGE-3 has been shown to complex with HLA-A1. MAGE-
  • MAGE-12 is significantly expressed in a number of tumors of different histological type (dePlaen et al., Immunogenetics 40: 360-369 (1994), supra) and may produce tumor rejection antigens (dePlaen et al. (1994), supra; deSmet et al., Immunogenetics 39: 121-129 (1994)), the determination of the DNA and amino acid sequences of MAGE-12 (NCBI database accession 154519; GenBank database accession LI 8877; dePlaen et al.
  • the present invention provides an isolated and purified polypeptide consisting essentially of the amino acid sequence VRIGHLYIL (SEQ ID NO: 1).
  • the present invention further provides an isolated and purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding the amino acid sequence VRIGHLYIL, such as SEQ ID NO: 2.
  • a vector comprising and expressing such a nucleic acid molecule and a cell comprising such a vector.
  • a composition comprising the polypeptide in an amount effective to induce an immune response to the polypeptide in a mammal as well as a composition comprising the vector in an amount sufficient to express an immune response-inducing amount of the polypeptide VRIGHLYIL in a mammal are also provided.
  • a method of inducing an immune response to a cancer in a mammal having cancer, such as melanoma is provided. The method comprises administering to the mammal the composition comprising the polypeptide or the vector, whereupon an immune response to the cancer in the mammal is induced.
  • the mammal has HLA-Cw*0702.
  • the method can further comprise administering a cytokine, such as interleukin-2.
  • FIG. 1 represents the nucleotide (line a; SEQ ID NO: 3) and deduced amino acid (line c; SEQ ID NO: 4) sequences of MAGE-12 as compared to the nucleotide (line b; SEQ ID NO: 5) and deduced amino acid (line d; SEQ ID NO: 6) sequences of MAGE-12 published in GenBank.
  • the present invention is predicated, at least in part, on the surprising and unexpected discovery of a T-cell epitope in the cancer-specific antigen MAGE-12 at amino acids 170-178.
  • the epitope is recognized by tumor-infiltrating lymphocytes.
  • the epitope is advantageous in that it provides a tumor rejection antigen for a large segment i.e., approximately 20%, of the population afflicted with melanoma, which expresses the cell-surface MHC-class I molecule HLA-Cw*0702 and for which no tumor rejection antigen is currently available for induction of an immune response to cancer. While the epitope is particularly useful in the treatment of melanoma, given that MAGE-12 is found on most tumors, the epitope has widespread utility in cancer immunotherapy.
  • the present invention provides an isolated and purified polypeptide consisting essentially of the amino acid sequence VRIGHLYIL (SEQ ID NO: 1).
  • the polypeptide can contain up to a few, such as one, two or three, additional amino acids, for example, at either or both ends as long as the additional amino acids do not interfere with the ability of the polypeptide to function in accordance with the present invention.
  • the polypeptide can comprise one or more variant amino acids, which desirably do not eliminate the ability of the polypeptide to function in accordance with the present invention and preferably improve the ability of the polypeptide to function in accordance with the present invention.
  • the generation of variant polypeptides is within the ordinary skill in the art (see, e.g.,
  • polypeptide can be easily synthesized by Merrifield synthesis or other pep tide synthesis methodologies.
  • GMP grade polypeptide is produced by solid-phase synthesis techniques by Multiple Peptide Systems, San Diego, CA.
  • the polypeptide also can be recombinantly produced, if so desired, in accordance with methods known in the art.
  • the polypeptide complexes with cell-surface MHC-class I HLA-Cw*0702 molecules.
  • the polypeptide can be used to identify whether or not HLA- Cw* 0702 -presenting cells are present in a sample.
  • the polypeptide can be contacted with a cell sample and the binding of HLA-Cw*0702 -presenting cells to the polypeptide can be determined using detection methods, such as radiolabeling or binding to a solid phase, known in the art.
  • the polypeptides and complexes thereof with HLA-Cw*0702 can be used in the generation of monoclonal antibodies or cytolytic T-cell clones specific for the polypeptides or complexes.
  • the production of antibodies is within the skill in the art as is the generation of a cytolytic T-cell clone (see, e.g., U.S. Patent No. 5,851,523).
  • Such monoclonal antibodies and cytolytic T-cell clones are useful reagents in diagnosing cancer; etc. Diagnostic assays, such as immunoassays and the chromium release assay, are known in the art.
  • Cytolytic T-cell clones are also useful in adoptive transfer and other therapeutic applications (see, e.g., U.S. Patent No. 5,558,995).
  • the present invention further provides an isolated and purified nucleic acid molecule consisting essentially of a nucleotide sequence encoding the amino acid sequence VRIGHLYIL.
  • Such a nucleic acid molecule can be synthesized in accordance with methods known in the art. Due to the degeneracy of the genetic code, one of ordinary skill in the art will appreciate that nucleic acid molecules of different nucleotide sequence can encode the same amino acid sequence.
  • the present invention also further provides a vector comprising and expressing an above-described isolated and purified nucleic acid molecule.
  • Suitable vectors are known in the art as is vector construction, including the selection of promoters and other regulatory elements, such as enhancer elements.
  • the vector utilized in the context of the present invention desirably comprises sequences appropriate for introduction into cells.
  • the vector can comprise an expression vector, a vector in which the coding sequence of the polypeptide is under the control of its own cts-acting regulatory elements, a vector designed to facilitate gene integration or gene replacement in host cells, and the like.
  • a "vector” encompasses a DNA molecule, such as a plasmid, bacteriophage, phagemid, virus or other vehicle, which contains one or more heterologous or recombinant DNA sequences, e.g., an above-described isolated and purified nucleic acid molecule, under the control of a functional promoter and, possibly, also an enhancer, and that is capable of functioning as a vector as that term is understood by those of ordinary skill in the art.
  • a DNA molecule such as a plasmid, bacteriophage, phagemid, virus or other vehicle, which contains one or more heterologous or recombinant DNA sequences, e.g., an above-described isolated and purified nucleic acid molecule, under the control of a functional promoter and, possibly, also an enhancer, and that is capable of functioning as a vector as that term is understood by those of ordinary skill in the art.
  • Appropriate phage and viral vectors include, but are not limited to, lambda ( ⁇ ) bacteriophage, EMBL bacteriophage, simian virus 40, bovine papilloma virus, Epstein-Barr virus, adenovirus, herpes virus, vaccinia virus, Moloney murine leukemia virus, Harvey murine sarcoma virus, murine mammary tumor virus, and Rous sarcoma virus.
  • a “gene” is any nucleic acid sequence coding for a polypeptide or protein or a nascent niRNA molecule. Whereas a gene comprises coding sequences plus any noncoding (e.g., regulatory) sequences, a “coding sequence” does not include any noncoding DNA.
  • a coding sequence encodes the amino acid sequence VRIGHLYIL (SEQ ID NO: 1) and consists essentially of a nucelotide sequence encoding the amino acid sequence of SEQ ID NO: 1, such as the nucleotide sequence of SEQ ID NO: 2.
  • a "promoter” is a DNA sequence that directs the binding of RNA polymerase and, thereby, promotes RNA synthesis.
  • “Enhancers” are -acting elements of DNA that stimulate or inhibit transcription of adjacent genes.
  • Enhancers differ from DNA-binding sites for sequence-specific DNA binding proteins found only in the promoter (which also are termed “promoter elements”) in that enhancers can function in either orientation, and over distances of up to several kilobase (kb) pairs, even from a position downstream of a transcribed region.
  • a vector according to the invention is compatible with the cell into which it is introduced, e.g., is capable of imparting expression on the cell of the coding sequence, and is stably maintained or relatively stably maintained in the host cell.
  • the vector comprises an origin of replication functional in the cell.
  • the vector When a coding sequence is transferred, optimally the vector also contains a promoter that can drive expression of the coding sequence and that is operably linked to the coding sequence.
  • a coding sequence is "operably linked" to a promoter gene when the promoter can direct transcription of the coding sequence.
  • a recombinant vector of the present invention preferably all the proper transcription (e.g., initiation and termination signals), translation (e.g., ribosome entry or binding site and the like) and processing signals (e.g., splice donor or acceptor sites, if necessary, and polyadenylation signals) are arranged correctly on the vector, such that the coding sequence will be appropriately transcribed and translated in the cells into which it is introduced.
  • transcription e.g., initiation and termination signals
  • translation e.g., ribosome entry or binding site and the like
  • processing signals e.g., splice donor or acceptor sites, if necessary, and polyadenylation signals
  • a native promoter or another promoter including a constitutive promoter, such as, for instance the adenoviral type 2 (Ad2) or type 5 (Ad5) major late promoter (MLP) and tripartite leader, the cytomegalovirus (CMV) immediate early promoter/enhancer, the Rous sarcoma virus long terminal repeat (RSV-LTR), and others, including promoters appropriate for expression in prokaryotic cells, can be employed to command expression of the coding sequence.
  • a constitutive promoter such as, for instance the adenoviral type 2 (Ad2) or type 5 (Ad5) major late promoter (MLP) and tripartite leader, the cytomegalovirus (CMV) immediate early promoter/enhancer, the Rous sarcoma virus long terminal repeat (RSV-LTR), and others, including promoters appropriate for expression in prokaryotic cells, can be employed to command expression of the coding sequence.
  • CMV cytomegalovirus
  • tissue-specific promoter i.e., a promoter that is preferentially activated in a given tissue and results in expression of a gene product in the tissue where activated
  • promoters include, but are not limited to, the elastase I gene control region, which is active in pancreatic acinar cells as described by
  • a promoter that is selectively activated at a particular developmental stage can be employed, e.g., globin genes are transcribed differentially in embryos and adults.
  • an inducible promoter such as the IL-8 promoter, which is responsive to TNF, or to use other similar promoters responsive to other factors present in a host or that can be administered exogenously.
  • any promoter can be altered by mutagenesis, so long as it has the desired binding capability and promoter strength.
  • the vector also comprises some means by which the vector or its contained subcloned sequences can be identified and selected.
  • Vector identification and/or selection can be accomplished using a variety of approaches known to those of ordinary skill in the art.
  • a vector comprising an above-described nucleic acid molecule can be identified by hybridization, the presence or absence of so-called "marker" gene functions encoded by marker genes present on the vectors, and/or the expression of particular sequences.
  • the presence of a particular sequence in a vector can be detected by hybridization (e.g., by DNA-DNA hybridization) using probes comprising sequences that are homologous to the relevant sequence.
  • the recombinant vector/host system can be identified and selected based upon the presence or absence of certain marker gene functions, such as resistance to antibiotics, thymidine kinase activity, and the like, caused by particular genes encoding these functions present on the vector.
  • vectors can be identified by assaying for a particular gene product, i.e., the T-cell epitope of MAGE- 12 (amino acids 170-178), encoded by the vector. Such assays can be based on the physical, immuno logical, or functional properties of the gene product.
  • the present invention further provides a cell comprising an above- described vector.
  • a vector according to the present invention can be introduced into any suitable host cell, whether eukaryotic or prokaryotic.
  • suitable prokaryotic host cells include, but are not limited to, Escherichia coli, Bacillis subtilis, Pseudomonas aeruginosa, and members of the genus Salmonella (e.g., S. typhimurium, S. typhi, S. enteritidis, and the like).
  • a prokaryotic host cell is avirulent.
  • Suitable eukaryotic host cells include, but are not limited to, rodent or mouse cells, Saccharomyces cerevisiae, and, particularly, human cells.
  • the vector comprises an expression vector appropriate for expression of a the coding sequence in a human or rat cell, or, alternately, in an E. coli cell.
  • an expression vector appropriate for expression of a the coding sequence in a human or rat cell or, alternately, in an E. coli cell.
  • the form of the introduced vector can vary with the rationale underlying the introduction of the vector into the host cell.
  • the nucleic acid can be closed circular, nicked, or linearized, depending on whether the vector is to be maintained extragenomically (i.e., as an autonomously replicating vector), integrated as a provirus or prophage, transiently transfected, transiently infected as with use of a replication- deficient or conditionally replicating virus or phage, or stably introduced into the host genome through double or single crossover recombination events.
  • vector introduction can be accomplished, for instance, by electroporation, transformation, transduction, conjugation or triparental mating.
  • vectors can be introduced through the use of, for example, electroporation, transfection, infection, membrane fusion with liposomes, high velocity bombardment with DNA-coated microprojectiles, incubation with calcium phosphate- DNA precipitate, direct microinjection into single cells, and the like. Other methods are available and are known to those skilled in the art.
  • compositions comprising the above-described polypeptide in an amount effective to induce an immune response (as described herein below) in a mammal to said polypeptide is further provided by the present invention.
  • a composition comprising an above-described vector in an amount sufficient to express an immune response-inducing amount (as described herein below) of the polypeptide VRIGHLYIL in a mammal is provided.
  • the composition comprises an excipient, such as a vehicle, adjuvant, carrier or diluent, which is desirably pharmaceutically acceptable, as are known in the art. See, for example, Pharmaceutics and Pharmacy Practice, J. B. Lippincott Co., Philadelphia, PA, Banker and Chalmers, eds. (1982) and ASHP Handbook on Injectable Drugs, Toissel, 4 th ed. (1986).
  • a composition suitable for use in the present inventive method comprises 1 mg of the polypeptide consisting essentially of the amino acid sequence VRIGHLYIL and Montanide ISA-51 (Seppic, Inc., Fairfield, NJ).
  • the composition is an emulsion that is suitable for injection.
  • the composition preferably is divided into two equal volumes (1 ml each), each of which is injected into the anterior thigh deep subcutaneous tissue within 2 cm of each other.
  • the polypeptide can be complex ed with liposomes.
  • the composition can further comprise the use of an immunoadjuvant, such as incomplete Freund's adjuvant.
  • the present invention further provides a method of inducing an immune response to a cancer in a mammal having the cancer.
  • the method comprises administering to the mammal a composition comprising the above- described polypeptide in an amount effective to induce an immune response to the polypeptide in the mammal.
  • the method comprises administering to the mammal a composition comprising an above-described vector in an amount sufficient to express an immune response-inducing effective amount of the polypeptide VRIGHLYIL in the mammal.
  • Any cancer that is characterized by the presentation of the T-cell epitope VRIGHLYIL, such as by the cell-surface MHC class I molecule HLA-CW*0703, can be treated in accordance with this method.
  • the cancer is melanoma, such as cutaneous melanoma or ocular melanoma.
  • melanoma such as cutaneous melanoma or ocular melanoma.
  • Non-small cell lung carcinoma, head and neck tumors, bladder carcinoma, esophageal carcinoma, sarcoma, and mammary and colorectal carcinomas are non- limiting examples of other cancers that can be treated in accordance with the present inventive method.
  • the mammal preferably has HLA-Cw*0702.
  • Suitable formulations of compositions that can be used in the present inventive methods.
  • the means of administration is determined, in part, by whether a polypeptide or a vector is being administered.
  • Suitable routes of administration include peritumoral, intratumoral, intravenous, intramuscular, intraperitoneal, intraurethral, subcutaneous, oral, rectal, intranasal, canulation of the ductal epithelium of the mammary gland, and the like.
  • Peritumoral and intratumoral routes of administration such as by injection, are preferred.
  • the dose administered to a mammal, particularly a human, in the context of the present invention should be sufficient to induce an immune response to a cancer in the mammal having the cancer over a reasonable time frame.
  • the dose will be determined, in part, by whether a polypeptide or a vector is employed for treatment, the severity of the cancer, as well as the body weight and age of the afflicted individual.
  • the dosage can be in unit dosage form, such as a tablet or capsule.
  • unit dosage form refers to physically discrete units suitable as unitary dosages for human and animal subjects, each unit containing a predetermined quantity of a polypeptide or vector, alone or in combination with other anticancer agents, calculated in an amount sufficient to induce an immune response, and other anti- cancer effects as desired, in association with a pharmaceutically acceptable diluent, carrier, or vehicle.
  • the specifications for the unit dosage forms of the present invention depend on the particular embodiment employed.
  • the dose administered should be an "immune response-inducing amount" or an "amount effective to induce an immune response" in the individual mammal.
  • the effective amount can vary, depending on interindividual differences in pharmacokinetics, drug distribution, and metabolism.
  • the effective amount can be defined, for example, as the blood or tissue level desired in the mammal that corresponds to a concentration of the polypeptide or vector according to the invention, which induces an immune response.
  • the effective amount also can vary when the compositions of the present invention are used in combination with other known anti- cancer agents.
  • One skilled in the art can easily determine the appropriate dose, schedule, and method of administration for the exact formulation of the composition being used, in order to achieve the desired effective amount in the individual mammal.
  • One skilled in the art also can readily determine and use an appropriate indicator of the effective amount of the composition of the present invention by a direct or indirect analysis of appropriate patient samples (e.g., blood and/or tissues).
  • the polypeptide is administered. If the polypeptide is administered, preferably it is administered every 1-3 weeks for four cycles, wherein four cycles equals one course. Preferably, a maximum of 24 injections is administered.
  • the vector is administered, generally, an amount of vector to achieve a tissue concentration of about 10 to about 10 12 particles per ml is preferred, especially of about 10 6 to about 10 10 particles per ml. In certain applications, multiple daily doses are preferred. Moreover, the number of doses will vary depending on the means of delivery and the particular vector administered.
  • suitable animal models are available and have been widely implemented for evaluating the in vivo efficacy against cancer of recombinant DNA protocols (see, e.g., PCR). These models include nude mice and SCTD mice. Such models also can be used to evaluate the in vivo efficacy of an RNA genome.
  • composition can contain other active agents when used to treat cancer therapeutically.
  • an anticancer agent be employed, such as, preferably, a recombinant virus, a nucleic acid/liposomal formulation (or other nucleic acid delivery formulation), or another vector system (e.g., retrovirus or adenovirus), either as a viral particle or as a nucleic acid/liposomal formulation.
  • additional pharmaceuticals include chemotherapeutic agents, immunostimulants, antiviral compounds, and other agents and treatment regimes (including those recognized as alternative medicine) that can be employed to treat cancer.
  • Anticancer compounds include, but are not limited to, angiostatin, endostatin, anti-HER-2/neu antibody, and tamoxifen.
  • Immunomodulators and immunostimulants include, but are not limited to, various interleukins, cytokines, antibody preparations, and interferons.
  • the method of the present invention further comprises administering a cytokine.
  • the cytokine can be any suitable cytokine in the context of cancer immunotherapy and includes all forms of such molecules, whether human, murine or other, and whether isolated from nature or produced recombinantly, as well as any and all variants of such molecules, provided that the variants have the same activity, whether to a greater or lesser extent.
  • the cytokine is interleukin-2 (IL-2).
  • IL-2 interleukin-2
  • Preferred amounts of a given cytokine to be administered by a given route are set forth in Biologic Therapy of Cancer, deVita, Hellman and Rosenberg, eds., J.P. Lippincott Co., Philadelphia, PA, 2 nd ed. (1995).
  • a cytokine such as IL-2, preferably recombinant human IL-2 (rhTL-2; available from Chiron; desirably reconstituted and preferably further diluted with human serum albumin), is administered in the context of the present inventive method, preferably it is administered as a high-dose intravenous bolus of 720,000 IU/kg over 15 min every 8 hrs, beginning on the day after immunization and continuing for up to 4 days for a maximum of 12 doses. Doses can and should be skipped if a patient develops grade III or IV toxicity, which can be easily reversed by temporarily discontinuing administration, such that additional doses of cytokine, e.g., rhIL-2, can be subsequently administered.
  • rhTL-2 recombinant human IL-2
  • cytokine itself, can be administered, a vector (as described above) encoding and expressing the cytokine at levels described above can be administered.
  • a universal immunomodulatory cytokine-expressing bystander cell line such as one that expresses IL-2, can be administered (see, e.g., Levitsky et al., WO 99/38954) such that the desired level of cytokine is achieved.
  • TIL Tumor-infiltrating lymphocyte
  • MEL melanoma
  • the TIL was designated F001-TIL and the MEL was designated F001-MEL (an early passage ( ⁇ 5 passages) melanoma cell line; (Riker et al., Cancer Detect. Prev. 23: 387 (1999)).
  • the cell lines were subjected to detailed functional and molecular testing.
  • HLA allele Cw*0702 was the restriction element for F001- TIL.
  • a CDNA library from F001-MEL transfected into interferon- ⁇ (IFN- ⁇ )- stimulated 293 human embryonal kidney cells expressing HLA-Cw*0702 identified a cDNA sequence homologous, except for one amino acid (amino acid 187 D ⁇ A), to MAGE-12 as the target antigen for FOOl -TIL.
  • Fig. 1 represents the nucleotide (line a) and deduced amino acid (line c) sequences of MAGE-12 derived from analysis of cDNA from FOOl -MEL.
  • sequences are aligned with the MAGE-12 nucleotide (line b) and deduced amino acid (line d) sequences available through GenBank (GenBank accession no. LI 8877).
  • the nucleotides and amino acids are numbered from the first codon and amino acid, respectively.
  • the variant residue and related nucleotide at position 187 are underlined.
  • the epitope recognized by FOOl -TEL is underlined (amino acids 170- 178).
  • amino acids 170-178 of MAGE-12 represents an epitope that interacts with the MHC class I molecule HLA-Cw*0702.
  • the resulting complex stimulates the production of cytolytic T-cell clones that lyse the presenting cells.
  • the epitope meets a long-felt need for a tumor rejection antigen in the large segment (i.e., 20%) of patients with melanoma for which no tumor rejection was previously available.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne un polypeptide isolé et purifié constitué essentiellement de la séquence d'acides aminés VRIGHLYIL, une molécule d'acide nucléique isolée et purifiée constituée essentiellement d'une séquence nucléotidique codant pour la séquence d'acides aminés VRIGHLYIL, telle que SEQ ID NO:2, un vecteur contenant et exprimant cette molécule d'acide nucléique isolée et purifiée et une cellule contenant ce vecteur. L'invention concerne en outre une composition renfermant le polypeptide isolé et purifié ou le vecteur dans une quantité capable d'induire chez un mammifère une réaction immunitaire à l'égard du polypeptide, ainsi qu'un procédé visant à induire chez un mammifère atteint de cancer, p. ex. de mélanome, une réaction immunitaire à un cancer. Le procédé comporte l'administration au mammifère de cette composition, qui contient de préférence HLA-Cw*0702, dans une quantité capable d'induire chez ce mammifère une réaction immunitaire au cancer. Le procédé peut comporter en outre l'administration d'une cytokine telle que l'interleukine 2.
PCT/US2001/010312 2000-03-30 2001-03-29 Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer WO2001074847A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001253029A AU2001253029A1 (en) 2000-03-30 2001-03-29 T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19320600P 2000-03-30 2000-03-30
US60/193,206 2000-03-30

Publications (2)

Publication Number Publication Date
WO2001074847A2 true WO2001074847A2 (fr) 2001-10-11
WO2001074847A3 WO2001074847A3 (fr) 2002-03-21

Family

ID=22712651

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010312 WO2001074847A2 (fr) 2000-03-30 2001-03-29 Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer

Country Status (2)

Country Link
AU (1) AU2001253029A1 (fr)
WO (1) WO2001074847A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306131B2 (en) * 2011-09-15 2022-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031017A1 (fr) * 1996-02-20 1997-08-28 Ludwig Institute For Cancer Research Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999061916A1 (fr) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification d'epitopes dr de restriction largement reactifs
WO2000052045A2 (fr) * 1999-02-26 2000-09-08 Fondazione Centro San Raffaele Del Monte Tabor Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
WO2001000225A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
WO2001029220A2 (fr) * 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Peptides antigeniques mage-a12 et utilisation

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997031017A1 (fr) * 1996-02-20 1997-08-28 Ludwig Institute For Cancer Research Antigenes de rejet tumoral presentes par des molecules hla-b44 et utilisations de ces derniers
WO1999045954A1 (fr) * 1998-03-13 1999-09-16 Epimmune, Inc. Peptides de liaison de hla et leurs applications
WO1999061916A1 (fr) * 1998-05-29 1999-12-02 Epimmune, Inc. Identification d'epitopes dr de restriction largement reactifs
WO2000052045A2 (fr) * 1999-02-26 2000-09-08 Fondazione Centro San Raffaele Del Monte Tabor Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
WO2001000225A1 (fr) * 1999-06-29 2001-01-04 Epimmune Inc. Peptides de liaison a hla et leurs utilisations
WO2001029220A2 (fr) * 1999-10-19 2001-04-26 Ludwig Institute For Cancer Research Peptides antigeniques mage-a12 et utilisation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HEIDECKER, LEONORA ET AL: "Cytolytic T lymphocytes raised against a human bladder carcinoma recogniz an antigen encoded by gene MAGE-A12" J. IMMUNOL. (2000), 164(11), 6041-6045 , XP002173646 *
PANELLI, MONICA C. ET AL: "A tumor-infiltrating lymphocyte from a melanoma metastasis with decreased expression of melanoma differentiation antigens recognizes MAGE-12" J. IMMUNOL. (2000), 164(8), 4382-4392 , XP002173647 *
PLAEN DE E ET AL: "STRUCTURE, CHROMOSOMAL LOCALIZATION, AND EXPRESSION OF 12 GENES OF THE MAGE FAMILY" IMMUNOGENETICS, SPRINGER VERLAG, BERLIN, DE, vol. 40, no. 5, 1994, pages 360-369, XP000614537 ISSN: 0093-7711 cited in the application *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11306131B2 (en) * 2011-09-15 2022-04-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-CW7-restricted mage

Also Published As

Publication number Publication date
AU2001253029A1 (en) 2001-10-15
WO2001074847A3 (fr) 2002-03-21

Similar Documents

Publication Publication Date Title
KR100752065B1 (ko) Ｗｔ1 특이적 면역요법용 조성물 및 방법
ES2326311T3 (es) Composiciones y metodos para inmunoterapia especifica con wt1.
ES2311027T3 (es) Composiciones y metodos para la inmunoterapia especifica de wt1.
US7915393B2 (en) Compositions and methods for WT1 specific immunotherapy
US5550214A (en) Isolated antigenic oncogene peptide fragments and uses
US8535690B2 (en) Tumor specific animal proteins
US20100209386A1 (en) Agonist and antagonist peptides of carcinoembryonic antigen (cea)
AU745863B2 (en) Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
JP4097178B2 (ja) 腫瘍抗原
WO2001074847A2 (fr) Epitope de lymphocyte t de mage-12 et acides nucleiques, vecteurs et cellules correspondants, compositions et procedes induisant une reaction immunitaire a un cancer
JP2012039877A (ja) ユビキチン融合遺伝子およびそれを用いたｄｎａワクチン
US6664232B1 (en) HLA-A2 restraint tumor antigen peptide originating in SART-1
EP1447414B1 (fr) Peptides antagonistes de l'antigène carcinoembryonnaire
JP2004000216A (ja) 腫瘍抗原
WO2002006338A1 (fr) Vaccin comprenant un antigene associe a une tumeur du poumon
US7811574B2 (en) Tumour-specific animal proteins
JP4705697B2 (ja) Ｍｎ／ｃａ９由来のｈｌａ−ａ２４拘束性腫瘍抗原ペプチド
CN115490763A (zh) Lum的表位肽及所述表位肽与热休克蛋白的复合物
US20020192229A1 (en) MHC class I associated peptides for prevention and treatment of tuberculosis
CN115491369A (zh) Pdia3的表位肽及所述表位肽与热休克蛋白的复合物
WO2000002907A1 (fr) Peptide antigene tumoral produit dans le sart-1
ZA200206746B (en) Tumour-specific animal proteins.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP